In this phase, pharmacokinetics takes center stage. A drug might work in a petri dish, but can it survive the acidic environment of the stomach? Will it cross the blood-brain barrier?
How the drug enters the bloodstream (e.g., oral, intravenous, subcutaneous).
Before a drug ever touches a human, regulators (like the FDA or EMA) require extensive preclinical data. Pharmacology is central to two types of studies:
, and begins with thousands of candidates to find just one success. Phase 1: The Detective Work (Discovery) pharmacology in drug discovery and development
Drug discovery begins with a disease hypothesis. Pharmacology steps in to validate the biological target—typically a receptor, enzyme, ion channel, or nucleic acid. Using tools like CRISPR-Cas9, RNA interference, and monoclonal antibodies, pharmacologists confirm that modulating this target will indeed produce a therapeutic effect.
The PD effect is quantified using a , which relates the drug concentration at the site of action to the magnitude of the observed effect. This curve yields crucial metrics like potency (EC50) , the concentration required to produce 50% of the maximal effect, and efficacy , the maximum effect a drug can produce regardless of dose.
The journey doesn't end when the drug hits the pharmacy shelf. In this phase, pharmacokinetics takes center stage
Are you interested in a (e.g., small molecules vs. biologics)? Is this for exam prep or a general overview ?
In 2006, this CD28 superagonist caused catastrophic multi-organ failure in six healthy volunteers within hours. The failure was . Preclinical studies in cynomolgus monkeys used a different CD28 expression profile on T-cells. Human T-cells were hyper-responsive. Outcome: New era of in vitro human cell-based assays (e.g., using human peripheral blood mononuclear cells) before FIH trials.
Before a human ever touches the drug, it undergoes rigorous "in vitro" (test tube) and "in vivo" (animal) testing. Pharmacologists focus on two main areas: Pharmacology in Drug Discovery and Development - Elsevier How the drug enters the bloodstream (e
The data generated from these pharmacological and toxicological studies form the foundation of the , which a sponsor must submit to the FDA (or similar regulatory agency) before beginning human clinical trials.
The future of pharmacology is personalized. Genetic variants in CYP2C19 (affecting clopidogrel activation) or HLA-B*5701 (abacavir hypersensitivity) are now pre-screened. Regulatory agencies now encourage or mandate pharmacogenomic labeling. Discovery teams are designing "companion diagnostics" alongside drugs to identify responders.
This shift is driving the field of , whose explicit goal is to bridge the gap between promising in vitro and in vivo results and a successful clinical outcome. By leveraging AI, novel human-cell-based models, and human genetic data, scientists are building more predictive systems that reduce the industry's reliance on animal testing and increase the probability of success in the clinic.
[Phase 1: Safety & PK] ──► [Phase 2: Efficacy & Dose] ──► [Phase 3: Confirmatory] ──► [Phase 4: Post-Market] Use code with caution.